NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»12/04/2010 [Independent reports]
Forecast 2015: The Next BIG trends

The pharmaceutical industry in the last few years has adapted various strategies like shifting R&D focus, reorganizing business units, outsourcing manufacturing and R&D, and retrenchment of employees to improve productivity.

The pharmaceutical industry in the last few years has adapted various strategies like shifting R&D focus, reorganizing business units, outsourcing manufacturing and R&D, and retrenchment of employees to improve productivity. Asian powerhouses like India, China, Korea and Singapore with skilled work force, effective regulatory system, government support, and cheap labor, have offered platform for the big pharma to join hands with the local companies for collaborations. Utilising the opportunities, companies from Asian region have emerged as leading service providers in contract research, manufacturing and clinical services. Asia is rapidly becoming the hub for global R&D. Contract manufacturing for pharmaceuticals and medical devices are also on the rise. Under the current changing global economics, BioSpectrum has identified four trends that will play an important role in shaping the life sciences industry in near future. Also, in the following pages of this special report there are insights from industry leaders on the complexion of the industry in 2015. Healthcare for ageing Globally, the population of older people is growing at a rate of 2.6 percent per year, considerably faster than the population as a whole, which is increasing at 1.2 percent annually. According to UN Department of Economic and Social Affairs Population Division report, between 2006-30, the number of older people in less developed countries is projected to increase by over 140 percent as compared to an increase of 51 percent in developed countries. Hence governments in both developed and developing world have launched programs to support the massive aging population. Datamonitor noted that the pharma companies will face growing competition from generics, due to increasingly tough pricing and reimbursement, a clamp down on healthcare spending, and the need to treat patients for longer due to the aging population. These factors prompt pharma companies to adopt a range of corporate strategies to respond to the changing market dynamics. Personalised medicine Recent developments in molecular profiling technologies, including proteomic profiling, metabolomic analysis, and genomic/genetic testing allow the development of personalised medicine and predictive medicine. Personalised medicine will allow healthcare providers to focus their attention on factors specific to a patient to provide individualised care. Companies from different spheres such as informatics IT, health insurance, consumer genetic testing, biotech and pharmaceuticals, and diagnostics are already working on this area. Outsourcing of research and manufacturing Increasing R&D costs, low productivity and profit margins, have forced the big pharma companies to look for outsourcing part of their research, clinical trials and manufacturing activities to low cost countries there by saving on costs and time. In the current era of globalization and competitive market, outsourcing has become the norm for pharma companies. Taking the advantage of the opportunities, Frost & Sullivan noted that companies from Asian region, will take away a major share of outsourcing from developed world. Biosimilars Biosimilars or generic biologic drugs are marketed around the world but are still restricted in the US. This may soon change. While Japan has already given the green signal for biosimilar product and the US is moving closer to the establishment of an approval pathway; the biosimilars market is set for imminent expansion. Datamonitor noted that the biosimilars market will grow across the seven major markets by 2014 following key patent expiry on epoetin alpha, filgrastim, interferon beta 1a, interferon alpha, human growth hormone (HGH), and insulin-glargine.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.